parasites of the P. falciparum FVO strain. Three to 13 days after the onset of patency, monkeys were treated by orogastric intubation with either JPC-2997 alone or JPC-2997 plus artesunate. After treatment of the monkeys, thick and thin blood smears were examined daily by counting parasitized erythrocytes against 200 leukocytes or 10,000 erythrocytes. When no parasites were detected in 100 microscopic high-power (ϫ1,000) fields, follow-up blood thick smears were examined twice a week for 3 weeks after parasite inoculation and then approximately once a week up to at least day 60 after parasite inoculation. The study was approved by the AMI Animal Ethics Committee (protocol AEC 10-13).
Regimens evaluated and parasite responses after treatment with JPC-2997 alone and in combination with artesunate are summarized in Table 1 . The 1-day JPC-2997 (20 mg/kg of body weight) treatment cleared parasites as rapidly as the two 3-day treatment courses of JPC-2997 (10 or 20 mg/kg/day), with Ͼ99% reduction in parasitemia by day 3 after starting treatment. None of the 4 naive monkeys had a recrudescence after administration of the three JPC-2997 regimens.
Previously, we reported that artesunate administered at 10 mg/kg daily for 3 days rapidly cleared parasites in Aotus monkeys infected with the P. falciparum FVO strain but that recrudescence occurred between days 9 and 20 (4). In the present study, a 1-day treatment of JPC-2997 (20 mg/kg) plus artesunate (10 mg/kg) administered to 4 monkeys (2 naive and 2 infected with CAP) with rising high parasitemia (range, 264.4 to 512.8 parasites ϫ 10 3 /l) cleared parasites by day 4 postdose, with no recrudescence observed over a 60-day follow-up period. Although the 1-day treat- a AS, artesunate; CAP, monkeys were exposed to chemically attenuated parasites 101 days before being challenged with the FVO strain; semi-immune, monkeys had been infected 101 days previously with the FVO strain and treated with JPC-2997 (10 mg/kg daily for 3 days or a single dose of 20 mg/kg); ND, not determined; NPS, no parasites seen. Day 0 is the day of treatment. Other days are the days after treatment was started. Nine Aotus monkeys were tested. Single and double asterisks indicate the same monkey. Parasite recrudescence was nil for all drugs. The follow-up period was at least 60 days after starting treatment.
ment with JPC-2997 plus artesunate cured the FVO infections, parasite clearance was more rapid when a 3-day course of artesunate at 10 mg/kg daily was used, with no parasites seen on day 3 after starting treatment of an initial parasite load of 145 to 515 parasites ϫ 10 3 /l (4). The lack of recrudescence reported in this study following treatment of FVO infections with either JPC-2997 alone or JPC-2997 in combination with artesunate provides further evidence of the in vivo potency and long prophylactic activity of JPC-2997. These findings suggest that JPC-2997 is a promising long-acting candidate antimalarial drug.
